Last reviewed · How we verify
NCT05174377: CADx
CADx - Radiomics to Distinguish the Origin of Ovarian Tumors
trial testing CT-scan algorithm in Ovarian Cancer in 600 participants. Status unknown.
1 August 2024
Quick facts
| Lead sponsor | Gynaecologisch Oncologisch Centrum Zuid |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 5 April 2021 |
| Primary completion | 1 August 2024 |
| Estimated completion | 1 August 2025 |
| Sites | 5 locations across Netherlands |
Drugs / interventions tested
- CT-scan algorithm
Conditions studied
- Ovarian Cancer — all drugs for Ovarian Cancer →
Sponsor
Gynaecologisch Oncologisch Centrum Zuid — full company profile →
Who can join
18 and older, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In women with an ovarian tumor, it is often unclear whether the tumor is benign or malignant. To differentiate, tumor markers (CA125 and CEA), a transvaginal ultrasound and, depending on the ultrasound image and the CA125 concentration, a CT scan are performed. The quality of radiological imaging in diagnosing abdominal pathology is often not accurate enough, making additional interventions no-dig for proper classification and interpretation of the tumor. Objective: To improve accuracy for distinguishing benign from malignant disease in patients presenting with an ovarian mass by using a computer aided detection algorithm.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Analysis of computer-aided diagnostics in the preoperative diagnosis of ovarian cancer: a systematic review.
Koch AH, Jeelof LS, Muntinga CLP, Gootzen TA, et al · · 2023 · cited 13× · PMID 36790570 · DOI 10.1186/s13244-022-01345-x
Verify or expand the search:
- PubMed search for NCT05174377
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ovarian Cancer
Currently open trials in the same condition.
- NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
- NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Gynaecologisch Oncologisch Centrum Zuid trials
Trials by the same sponsor.
- NCT03458221 — Signal TrAnsduction Pathway Activity Analysis in OVarian cancER · Phase 2, PHASE3 · recruiting
- NCT04022863 — Ovarium Cancer Detection by TEP's and ctDNA · unknown
- NCT07259616 — Incidence of Cervical Cancer in HPV-positive Women With Low-grade Cytological Abnormalities · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05174377 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gynaecologisch Oncologisch Centrum Zuid
- Last refreshed: 25 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05174377.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing